📉 Insulin Resistance Deep Dive

What this panel can settle, and by what logic

This panel exists because Fasting Insulin alone has two well-known failure modes, and the other eight markers are chosen to close them.

1. C-Peptide, Serum beside insulin settles whose insulin it is. Insulin and C-peptide are secreted in equal amounts, but insulin is largely extracted by the liver on its first pass and C-peptide is not, so C-peptide is the better read on what the pancreas actually made. When the two disagree, that discordance is itself the finding and it has a short differential: exogenous insulin, and insulin antibodies Teoli 2024.
2. Fructosamine fills the window between the other two. It reflects glycation over roughly 2 to 3 weeks against HbA1c (Hemoglobin A1c)'s 2 to 3 months Krhač 2019, which makes it the marker that moves first after a real change — and the marker to use at all when HbA1c is unreliable, which happens more often than most people expect Chen 2022.
3. SHBG (Sex Hormone-Binding Globulin) is the underused one. Hepatic sex hormone-binding globulin production is suppressed by insulin, so a low SHBG in someone with no hormonal complaint is a liver-level insulin signal that appears before the Comprehensive Metabolic Panel (CMP) shows anything. It costs $25 and most people who have it drawn are looking at a different question entirely.
4. Uric Acid and the triglyceride to HDL ratio corroborate cheaply. Three independent surrogates pointing the same way is a stronger statement than one insulin value, which is the argument for the bundle over the single test.

What it cannot settle, and what would

It cannot give you a number that means the same thing at another laboratory. Five C-peptide immunoassays compared across analyzers, all traceable to international reference standards, still differed significantly across the clinically relevant range, and the largest mean bias between two of them was 36.6% Hörber 2023. Insulin assays carry the same problem. The consequence is concrete: a HOMA-IR of 2.4 from this panel and a HOMA-IR of 2.4 from a different provider next year are not the same measurement, and the trend between them is partly a trend in laboratories. Repeat on the same platform or the series means nothing.

It cannot see the postprandial excursion. Every marker here is either fasting or an average, and glycemic variability in nondiabetic people is measurably higher in prediabetes than in health Kashiwagi 2023 without either of those two categories of marker moving. A continuous glucose monitor is the instrument for that question.

It cannot diagnose type 1 diabetes or LADA, which is the one urgent thing a low C-Peptide, Serum raises. Confirming it needs GAD, IA-2 and zinc transporter 8 autoantibodies, none of which is on this list Teoli 2024. A low C-peptide with a high glucose is a same-week clinical problem, not a nutrition problem.

And it cannot separate hepatic from peripheral insulin resistance. HOMA-IR is dominated by hepatic glucose output and tells you little about muscle; the clamp study that separates them is a research procedure Krhač 2019.

Draw conditions that decide whether the money is wasted

Insulin is the most fragile marker on this site between the needle and the analyzer, and none of the ways it breaks are visible on the report.

1. 9 to 12 hours fasted, in the morning, water only. Insulin responds to food within minutes and the reference interval it is read against is a fasting one Krhač 2019.
2. Ask for the sample to be spun and separated promptly, and reject a hemolyzed one. Red cells contain insulin-degrading enzyme, and hemolysis is one of the classic preanalytical interferences on immunoassays Caruso 2020. A traumatic draw lowers insulin and therefore lowers HOMA-IR, which is the direction that produces a falsely reassuring result.
3. No unusually large carbohydrate load and no hard session within 48 hours. Both move insulin sensitivity for a day or more, in opposite directions, and either one is larger than the change you are trying to detect.
4. Use one laboratory and one platform for the whole series. Given a 36.6% bias between two commercial assays Hörber 2023, switching provider between draws manufactures a change that did not happen.

How you would know it answered your question, and what each pattern means next

Four patterns, and the retest interval comes from which marker answered.

• High Fasting Insulin with normal glucose: the target state for this purchase. Change the inputs and re-measure at 8 to 12 weeks; Fructosamine will move at 3 weeks and is the early read on whether anything is happening Krhač 2019.
• Low C-Peptide, Serum with a high glucose: stop reading this as an insulin resistance result. It is the opposite problem, it needs autoantibodies and a clinician within days, and no retest interval applies Teoli 2024.
• HbA1c (Hemoglobin A1c) and Fructosamine disagreeing: believe fructosamine for recent weeks and suspect the HbA1c, because red cell lifespan and hemoglobin structure both change what an HbA1c reports Chen 2022. A Complete Blood Count (CBC) with Differential is the cheapest way to find the reason.
• Everything in range and the weight still will not move: the fasting picture is clean and what remains is the post-meal one. That is 14 days of continuous monitoring Kashiwagi 2023, not a repeat of these nine markers in 3 months.

Sources read for these sections

• Hörber S, et al. Comparability of C-Peptide Measurements - Current Status and Clinical Relevance. Experimental and Clinical Endocrinology and Diabetes 2023 · PMID 36630986
• Krhač M, Lovrenčić MV. Update on biomarkers of glycemic control. World Journal of Diabetes 2019 · PMID 30697366
• Chen Z, et al. Interpretation of HbA1c lies at the intersection of analytical methodology, clinical biochemistry and hematology (Review). Experimental and Therapeutic Medicine 2022 · PMID 36382101
• Kashiwagi K, et al. Assessment of glycemic variability and lifestyle behaviors in healthy nondiabetic individuals according to the categories of body mass index. PLoS One 2023 · PMID 37792730
• Teoli J, et al. When discordant insulin and C-peptide levels lead to a medical diagnosis in a patient with transient hypoglycemia: Varying degrees of interference of insulin-antibody complexes on three insulin immunoassays. Heliyon 2024 · PMID 39071705
• Caruso B, et al. Causes of Preanalytical Interferences on Laboratory Immunoassays - A Critical Review. EJIFCC 2020 · PMID 32256291